Pharmacokinetics and safety of ixazomib plus lenalidomide-dexamethasone in Asian patients with relapsed/refractory myeloma: a phase 1 study

• Main Authors: Gupta, N, Goh, Y.T, Min, C.-K, Lee, J.H, Kim, K, Wong, R.S.M, Chim, C.S, Hanley, M.J, Yang, H, Venkatakrishnan, K, Hui, A.-M, Esseltine, D.-L, Chng, W.J
• Other Authors: DUKE-NUS MEDICAL SCHOOL
• Format: Article
• Published: 2020
• Subjects: alanine aminotransferase; alkaline phosphatase; dexamethasone; gamma glutamyltransferase; ixazomib; lenalidomide; antineoplastic agent; boron derivative; glycine; thalidomide; adult; alanine aminotransferase blood level; alkaline phosphatase blood level; anemia; area under the curve; Article; cancer combination chemotherapy; decreased appetite; diarrhea; drug absorption; drug dose reduction; drug half life; drug response; drug safety; drug tolerability; East Asian; fatigue; female; gamma glutamyl transferase blood level; human; hypokalemia; insomnia; major clinical study; male; maximum plasma concentration; multiple cycle treatment; myeloma; nausea; neutropenia; peripheral neuropathy; phase 2 clinical trial; phase 3 clinical trial; relapse; side effect; skin disease; thrombocyte count; thrombocytopenia; time to maximum plasma concentration; treatment duration; vomiting; aged; analogs and derivatives; Asia; clinical trial; middle aged; multiple myeloma; phase 1 clinical trial; recurrent disease; Adult; Aged; Antineoplastic Agents; Boron Compounds; Dexamethasone; Female; Glycine; Humans; Male; Middle Aged; Multiple Myeloma; Recurrence; Thalidomide
• Online Access: https://scholarbank.nus.edu.sg/handle/10635/180875
• Institution: National University of Singapore

10.1186/s13045-015-0198-1